For patients with psoriasis in a real-world setting, tildrakizumab improved HRQOL and patient-reported
symptoms, according to a study published in The Journal of Dermatological Treatment. Neal Bhatia, MD, and
colleagues administered tildrakizumab 100 mg at weeks 0,4, and every 12 weeks thereafter in a 28-week
interim analysis of a 64-week phase 4 study.
Improvement from baseline in Dermatology Life Quality Index (DLQI), Psychological General
Well-Being Index (PGWBI), and Itch-, Pain-, and Scaling-Numerical Rating Scale scores through week
28, were the endpoints. At week 28, 53 of 55 patients were assessed. Positive well-being (1.0
[2.9]; P=0.018) and general health (1.5 [2.2]; P<0.001) domain scores improved, as well as mean
SD total PGWBI score from baseline to week 28 (change, 3.7 [12.4]; P=0.033), and the mean (SD) DLQI
score by −3.9 (4.3) at week 4 and by −7.6 (5.1) at week 28 (P<0.001). Starting at week 4, patient-
reported symptoms improved (P<0.001).
